Literature DB >> 8363390

In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid.

J S Knapp1, A F Back, A F Babst, D Taylor, R J Rice.   

Abstract

We determined the in vitro susceptibilities of 54 isolates of Haemophilus ducreyi from Thailand (29 isolates) and San Francisco (25 isolates) to penicillin G, tetracycline, amoxicillin-clavulanic acid, ceftriaxone, cefixime, erythromycin, azithromycin, ciprofloxacin, ofloxacin, and trimethoprim-sulfamethoxazole. Isolates were susceptible to < or = 0.25 microgram of ceftriaxone per ml, < or less 0.5 microgram of cefixime per ml, < or = 0.125 microgram of ciprofloxacin per ml, and < or = 0.06 microgram of ofloxacin per ml. Erythromycin was active against all isolates (MIC for 90% of isolates tested, 0.25 microgram/ml), as was azithromycin (MIC, < or = micrograms/ml). In contrast, all but one isolate were resistant to > or = 8.0 micrograms of tetracycline per ml, 11.1% of the isolates were resistant to and 40.9% of the isolates were resistant to trimethoprim-sulfamethoxazole (MIC, > or = 4/76 microgram/ml.)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363390      PMCID: PMC188012          DOI: 10.1128/AAC.37.7.1552

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Antimicrobial susceptibilities of southern African isolates of Haemophilus ducreyi.

Authors:  Y Dangor; S D Miller; F da L Exposto; H J Koornhof
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

2.  In-vitro susceptibility of thirty strains of Haemophilus ducreyi to several antibiotics including six cephalosporins.

Authors:  M J Sanson-Le Pors; I Casin; M Ortenberg; Y Perol
Journal:  J Antimicrob Chemother       Date:  1983-03       Impact factor: 5.790

3.  Synergistic antibacterial activity of clavulanic acid and amoxicillin against beta-lactamase-producing strains of Haemophilus ducreyi.

Authors:  Y C Girouard; I W Maclean; A R Ronald; W L Albritton
Journal:  Antimicrob Agents Chemother       Date:  1981-07       Impact factor: 5.191

4.  Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa.

Authors:  D Abeck; A P Johnson; Y Dangor; R C Ballard
Journal:  J Antimicrob Chemother       Date:  1988-10       Impact factor: 5.790

5.  Plasmid-mediated sulfonamide resistance in Haemophilus ducreyi.

Authors:  W L Albritton; J L Brunton; L Slaney; I MacLean
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

Review 6.  The treatment of chancroid.

Authors:  G P Schmid
Journal:  JAMA       Date:  1986-04-04       Impact factor: 56.272

7.  Comparative study of ceftriaxone and trimethoprim-sulfamethoxazole for the treatment of chancroid in Thailand.

Authors:  D N Taylor; C Pitarangsi; P Echeverria; K Panikabutra; C Suvongse
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

8.  Trimethoprim sulphamoxole in the treatment of chancroid. Comparison of two single dose treatment regimens with a five day regimen.

Authors:  J Dylewski; H Nsanze; L D'Costa; L Slaney; A Ronald
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

9.  Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.

Authors:  M Motley; S K Sarafian; J S Knapp; A A Zaidi; G Schmid
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 10.  Chancroid and Haemophilus ducreyi.

Authors:  S A Morse
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

View more
  7 in total

1.  Haemophilus ducreyi is susceptible to protegrin.

Authors:  K Fortney; P A Totten; R I Lehrer; S M Spinola
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

2.  Emergence of Haemophilus ducreyi resistance to trimethoprim-sulfamethoxazole in Rwanda.

Authors:  E Van Dyck; J Bogaerts; H Smet; W M Tello; V Mukantabana; P Piot
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

Review 3.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

Review 4.  Chancroid and Haemophilus ducreyi: an update.

Authors:  D L Trees; S A Morse
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

Review 5.  Quinolones in sexually transmitted diseases. Global experience.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1995       Impact factor: 9.546

6.  A (p)ppGpp-null mutant of Haemophilus ducreyi is partially attenuated in humans due to multiple conflicting phenotypes.

Authors:  Concerta Holley; Dharanesh Gangaiah; Wei Li; Kate R Fortney; Diane M Janowicz; Sheila Ellinger; Beth Zwickl; Barry P Katz; Stanley M Spinola
Journal:  Infect Immun       Date:  2014-06-09       Impact factor: 3.441

7.  Haemophilus ducreyi Cutaneous Ulcer Strains Are Nearly Identical to Class I Genital Ulcer Strains.

Authors:  Dharanesh Gangaiah; Kristen M Webb; Tricia L Humphreys; Kate R Fortney; Evelyn Toh; Albert Tai; Samantha S Katz; Allan Pillay; Cheng-Yen Chen; Sally A Roberts; Robert S Munson; Stanley M Spinola
Journal:  PLoS Negl Trop Dis       Date:  2015-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.